Kura Oncology Inc. (KURA)

Business: Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

IPO Date: 22-Sep-2015

Chairman, CEO, Pres & Principal Financial Officer: Dr. Troy Edward Wilson J.D., Ph.D.

Chief Operating Officer: Ms. Kathleen Ford

Listing: NASDAQ: KURA

Country: United States

Headquarters: San Diego, CA

Website: https://kuraoncology.com

Market cap: $1,091.83 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-132.23 Mln

Cash: $480.08 Mln

Total Debt: $6.39 Mln

Insider's Holding: 2.78%

Liquidity: Low

52 Week range: $10.41 - 23.00

Shares outstanding: 66,636,100

10 Years Aggregate:

• CFO: $-350.41 Mln
• EBITDA: $-438.84 Mln
• Net Profit: $-433.02 Mln